Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche: Essai mortalité et résistance (Azithromycin for Child Survival in Niger: Mortality Trial and Resistance Trial)
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings.Targeting treatment to children 1-11 months old could reduce antimicrobial resistance by limiting antibiotic distributions while treating children at the highest mortality risk. However, this targeted intervention has not yet been tested. The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of biannual azithromycin distribution on mortality as well as determine the impact of age-based targeting on antimicrobial resistance.
⁃ Location in Dosso, Tahoua, Maradi, Zinder, or Tillabéri regions
⁃ Population 250 to 2,499\*
⁃ Distance \> 5 km from district headquarters town
⁃ Distinguishable from neighboring communities
⁃ Verbal consent of community leader(s)
⁃ Age 1-59 months
⁃ Primary residence in a study community
⁃ Verbal consent of caregiver/guardian for study participation
⁃ Weight ≥ 3.0 kg (\*no weight limits in communities using age-based dosing)
• Location in Dosso
• Distinguishable from neighboring communities
• Verbal consent of community leader(s)
• Age 1-59 months or 7-12 years or caregiver/guardian of a child eligible for treatment
• Primary residence in a study community selected for sample collections
• Verbal consent of caregiver/guardian for study participation